Loading viewer...
earnings
Format: PDF earnings
Ambu reports Q2 and H1 2024/25 results with 15.4% organic revenue growth and 15.2% EBIT margin expansion. The company achieved a strong start for its Ambu® SureLight™ Connect launch in pulmonology and continued positive momentum in urology. Management confirms current FY 2024/25 financial guidance.
investor_presentation
13 Pages
earnings
8 Pages
CVR Partners
Watts Water Technologies 3Q 2021 Earnings Conference Call
earningsearnings
16 Pages
Watts Water Technologies